Trial Profile

An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Derazantinib (Primary)
Indications Bladder cancer; Carcinoma; Cholangiocarcinoma; Solid tumours; Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Acronyms FIDES-02
Sponsors Basilea Pharmaceutica

18 Feb 2023 Primary endpoint (objective response rate (ORR) has not been met according to results presented at the 2023 Genitourinary Cancers Symposium.
18 Feb 2023 Results assessing Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations presented at the 2023 Genitourinary Cancers Symposium
19 Oct 2022 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com